New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAdamax vs Thymosin Beta-4

Adamax vs Thymosin Beta-4

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Adamax
Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4
Summary
Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
Half-Life
Estimated 1-3 hours (short; peptide degradation)
Not well characterized; likely similar to TB-500 (~1–2 hours)
Admin Route
Subcutaneous, Intranasal (research)
SubQ, IM
Research
Typical Dose
200-400 mcg per dose
5–10 mg
Frequency
Once daily or every other day
2x per week (loading), then 1x per week (maintenance)
Key Benefits
  • Proposed enhancement of learning and memory consolidation
  • Neuroprotective via BDNF-TrkB pathway support
  • May improve mood and resilience to stress
  • Potential support for neurogenesis
  • Cognitive clarity and focus enhancement (reported anecdotally)
  • Explored for neurodegeneration and age-related cognitive decline
  • Systemic tissue repair and regeneration
  • Promotes cardiac recovery after myocardial infarction
  • Hair follicle regeneration and anti-hair-loss
  • Anti-inflammatory (systemic)
  • Wound healing acceleration
  • Neuroprotection after brain injury
  • Protects against ischemia-reperfusion injury
  • Anti-aging at cellular level
  • Synergizes powerfully with BPC-157
Side Effects
  • Limited human safety data; largely anecdotal reports
  • Possible headache or mild overstimulation
  • Sleep disruption with late-day dosing
  • Unknown long-term safety profile
  • Generally very well tolerated
  • Injection site reactions
  • Mild fatigue at initiation (repair signaling)
  • Rare: mild inflammatory response
  • +1 more
Stacks With